Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Halozyme Therapeutics Inc. (NASDAQ: HALO) was $63.74 for the day, down -1.06% from the previous closing price of $64.42. In other words, the price has decreased by -$1.06 from its previous closing price. On the day, 1.79 million shares were traded. HALO stock price reached its highest trading level at $65.5327 during the session, while it also had its lowest trading level at $63.6.
Ratios:
Our analysis of HALO’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.26 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.78. For the most recent quarter (mrq), Quick Ratio is recorded 6.21 and its Current Ratio is at 7.41. In the meantime, Its Debt-to-Equity ratio is 5.30 whereas as Long-Term Debt/Eq ratio is at 5.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on June 07, 2024, Downgraded its rating to Neutral and sets its target price to $51 from $48 previously.
On February 29, 2024, TD Cowen started tracking the stock assigning a Outperform rating and target price of $54.
On July 24, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $61.H.C. Wainwright initiated its Buy rating on July 24, 2023, with a $61 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 21 ’24 when LaBarre Michael J. sold 10,000 shares for $61.75 per share. The transaction valued at 617,470 led to the insider holds 168,176 shares of the business.
LaBarre Michael J. sold 10,000 shares of HALO for $610,550 on Aug 20 ’24. The SVP, CHIEF TECHNICAL OFFICER now owns 168,176 shares after completing the transaction at $61.05 per share. On Aug 21 ’24, another insider, MICHAEL LABARRE, who serves as the Officer of the company, bought 10,000 shares for $61.75 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HALO now has a Market Capitalization of 8074456064 and an Enterprise Value of 9078622208. As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 24.71, and their Forward P/E ratio for the next fiscal year is 13.30. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.88. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.25 while its Price-to-Book (P/B) ratio in mrq is 27.87. Its current Enterprise Value per Revenue stands at 10.396 whereas that against EBITDA is 18.882.
Stock Price History:
Over the past 52 weeks, HALO has reached a high of $65.00, while it has fallen to a 52-week low of $32.83. The 50-Day Moving Average of the stock is 15.36%, while the 200-Day Moving Average is calculated to be 46.06%.
Shares Statistics:
HALO traded an average of 1.36M shares per day over the past three months and 1348920 shares per day over the past ten days. A total of 126.77M shares are outstanding, with a floating share count of 125.31M. Insiders hold about 1.08% of the company’s shares, while institutions hold 97.16% stake in the company. Shares short for HALO as of 1723680000 were 9673467 with a Short Ratio of 7.09, compared to 1721001600 on 8708189. Therefore, it implies a Short% of Shares Outstanding of 9673467 and a Short% of Float of 10.35.
Earnings Estimates
A comprehensive evaluation of Halozyme Therapeutics Inc. (HALO) is underway, with the input of 8.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $1.28, with high estimates of $1.47 and low estimates of $1.12.
Analysts are recommending an EPS of between $4.1 and $3.77 for the fiscal current year, implying an average EPS of $3.96. EPS for the following year is $4.79, with 7.0 analysts recommending between $5.12 and $4.62.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 9 analysts. It ranges from a high estimate of $278.6M to a low estimate of $249.47M. As of the current estimate, Halozyme Therapeutics Inc.’s year-ago sales were $216.03MFor the next quarter, 9 analysts are estimating revenue of $307.19M. There is a high estimate of $338M for the next quarter, whereas the lowest estimate is $290.7M.
A total of 10 analysts have provided revenue estimates for HALO’s current fiscal year. The highest revenue estimate was $990M, while the lowest revenue estimate was $963.63M, resulting in an average revenue estimate of $984.22M. In the same quarter a year ago, actual revenue was $829.25MBased on 9 analysts’ estimates, the company’s revenue will be $1.14B in the next fiscal year. The high estimate is $1.18B and the low estimate is $1.11B.
